Skip to main content

Table 1 CONRAD 135 study design

From: Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies

Product

Visit 1

Visit 2

Visit 3

Visit 4

Visit 5

Intravaginal ring (IVR) (n = 20)

Screening

Insert IVR1

(24–36 h)

Remove IVR1

Vaginal swab

Insert IVR2 (7–10 days)

Remove IVR2

Vaginal swab

Insert IVR3 (28–32 days)

Remove IVR3

Vaginal swab

Gel, film, or insert (n = 10 each)

Screening

Baseline swab

Apply product in clinic

Swab 15 min post-product

Swabs at home each day, Day 1–Day 7

Baseline swab

Apply product in clinic

Swabs 15 min post-product

Unprotected intercourse 8–16 h post-product use

Swabs at home each day, Day 1–Day 7

Final swab

N/A